

SYMPOSIUM AGENDA

Saturday, March 1, 2025

9:30 AM – 2:30 PM

9:30 – 10:25 AM	Registration, Breakfast, Exhibitors
10:25 – 10:30 AM	Welcome/Opening Remarks Noura Elsedawy, MBBCh
10:30 – 10:45 AM	Setting the Stage: Pre-event Questions Noura Elsedawy, MBBCh, Moderator
10:45 – 11:10 AM	Updates in CML and MDS Swapna Thota, MD
11:10 – 11:30 AM	Updates in the Management of High-Risk Smoldering and Newly Diagnosed Multiple Myeloma Muhamed Baljevic, MD
11:30 – 11:50 AM	Updates in MPNs and Acute Leukemia Ashwin Kishtagari, MD
11:50 – 12:25 PM	Lunch, Exhibitors
12:25 – 12:45 PM	CAR-T Therapy for Multiple Myeloma: ASH Updates and Future Directions Othman Akhtar, MD
12:45 – 1:05 PM	Updates in Lymphoma Muhammad Saad Hamid, MD
1:05 – 1:25 PM	Updates on Cellular Therapy for Lymphomas and ALL Muthua Kumaran, MD
1:25 – 1:50 PM	Tumor Board Panel Case Discussion Noura Elsedawy, MBBCh, Moderator
1:50 – 2:05 PM	A Guided Discussion: Post-event Questions Noura Elsedawy, MBBCh, Moderator
2:05 – 2:20 PM	Question and Answer: All Presenters
2:20 – 2:30 PM	Closing Remarks Noura Elsedawy, MBBCh

REGISTRATION

Space is limited. Online registration is available at:
<https://cenow.uthsc.edu/content/2025-annual-updates-hematology-symposium>
There is no cost to attend this symposium.

ACTIVITY LOCATION

The University of Tennessee Health Science Center
Mooney Building, Library, Room 201
875 Monroe Avenue
Memphis, TN 38163

PARKING

Parking is available in the following two garages:

- **Hamilton Eye Institute Parking Garage (H Lot)**
Distance: 7-minute walk
Location: Madison Avenue at Pauline Street
(across from Landau Uniforms)
- **GEB Parking Garage (E Lot)**
Distance: 5-minute walk
Location: West of the College of Pharmacy building

CONTACT INFORMATION

Brelind Thompson

UT Health Science Center
Lead Cancer Conference Coordinator
Phone: 901.448.9758
Email: bremthom@uthsc.edu



*The University of Tennessee is an
EEO/AA/Title VI/Title IX/Section 504/ADA/ADEA
institution in the provision of its education and
employment programs and services.*

UT Health Science Center

ANNUAL UPDATES

in

HEMATOLOGY SYMPOSIUM

2025

Saturday, March 1, 2025

9:30 AM – 2:30 PM

The University of Tennessee
Health Science Center
Mooney Building Library, Room 201
875 Monroe Avenue
Memphis, TN 38163



OVERVIEW

The 2025 Annual Updates in Hematology Symposium is designed to provide hematology and oncology providers with a state-of-the-art update on hematologic malignancies and blood disorders. It will tackle the latest scientific updates, innovative ideas, and timeliest questions related to the management and care of these challenging conditions. It is also designed to provide a networking opportunity for healthcare professionals, who care for patients with blood cancers and disorders in the Mid-South, to establish collaborative pathways to improve the management and outcomes of this patient population.

EDUCATIONAL OBJECTIVES

- Develop and execute personalized treatment plans for patients with hematologic malignancies and blood disorders by utilizing guideline recommendations based on the evaluation of molecular and phenotypic biomarkers, along with precise disease sub-classification.
- Assess the latest clinical trial data on novel agents and emerging strategies for newly diagnosed and relapsed or refractory disease states.
- Discuss best strategies in managing treatment-related adverse events through agent familiarity and robust monitoring efforts.

DESIRED OUTCOME

The goal of the 2025 Annual Updates in Hematology Symposium is to provide participants with information to improve patient management and care strategies. This goal will be accomplished by discussing rapidly evolving developments and improved practice paradigms. The symposium will provide learners with enhanced knowledge of evidence-based data related to best practices for treating select blood cancers and disorders and inform them of the indications to refer patients for expert quaternary-level care. Panel discussions, along with question-and-answer sessions that include collaborative sharing of information and research, as well as networking with other healthcare professionals have shown to improve participant knowledge and competency. Additionally, it will build a connected community of hematologic care providers across the region.

FACULTY AND GUEST SPEAKERS



Othman S. Akhtar, MBBS
Assistant Professor
Department of Medicine, Division of
Hematology / Oncology
Medical College of Wisconsin



Muhamed Baljevic, MD
Associate Professor
Division of Hematology / Oncology
Director, Plasma Cell Disorders Research of
Vanderbilt-Ingram Cancer Center
Director, Vanderbilt Amyloidosis Multidisciplinary
Program (VAMP) of Vanderbilt-Ingram Cancer Center
Vanderbilt University



Noura Elsedawy, MD
Assistant Professor
Division of Hematology / Oncology
UT Health Science Center



Muhammad Saad Hamid, MD
Assistant Professor
Department of Hematology and Medical Oncology
Emory University School of Medicine



Ashwin Kishtagari, MD
Clinical Research Fellow, Bick Lab
Assistant Professor
Department of Medicine, Division of
Hematology / Oncology
Vanderbilt University



Muthu V. Kumaran, MD
Associate Professor and Section Chief
Department of Medicine, Division of
Hematology / Oncology
University of Arkansas Medical School



Swapna Thota, MD
Associate Professor
Division of Hematology / Oncology
UT Health Science Center

DISCLOSURE STATEMENT

The University of Tennessee College of Medicine is committed to providing CME that is balanced, objective, and evidence based. Individuals involved with planning, reviewing, and presenting content for this activity must disclose all relevant financial relationships with ineligible companies within the past 24 months, regardless of the amount. The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals must disclose regardless of their view of the relevance of the relationship to the education. The UT College of Medicine, the CME staff, and Activity Director have taken appropriate steps to identify and mitigate relationships prior to the individuals assuming their roles.

3.25 CME / CEU credits provided



AMA Credit Designation:

The University of Tennessee College of Medicine (UTCOM) designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Education for Non-Physicians:

The UTCOM will issue Certificates of Participation to non-physicians for participating in this activity and designates it for CEUs using the national standard that 1 hour of educational instruction is awarded .1 CEU.

Accreditation:

The UTCOM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



TARGET AUDIENCE

Primary care physicians, hematologists, pathologists, medical oncologists, nurse practitioners, fellows, residents, medical students, and other healthcare professionals dedicated to treating blood cancers and disorders.

ACTIVITY MEDICAL DIRECTOR

Noura Elsedawy, MD

Assistant Professor
Division Hematology / Oncology
UT Health Science Center